Pacific Biosciences of California, INC Form 4 insider transactions
NASDAQ
Susan G. Kim, CFO of Pacific Biosciences, sold 5,275 shares of common stock on March 4, 2024, to cover tax withholding obligations related to vesting restricted stock units.
NASDAQ
CEO Christian Henry sold 14,177 shares of Pacific Biosciences stock on March 4, 2024, to cover tax withholding obligations related to vesting restricted stock units.
NASDAQ
Director Marshall Mohr exercised stock options to acquire 25,000 shares of Pacific Biosciences common stock at a price of $4.45 on March 1, 2024.